Therapeutic angiogenesis in Buerger's disease: reviewing the treatment landscape.

Therapeutic advances in rare disease Pub Date : 2022-01-30 eCollection Date: 2022-01-01 DOI:10.1177/26330040211070295
Antoine J Ribieras, Yulexi Y Ortiz, Zhao-Jun Liu, Omaida C Velazquez
{"title":"Therapeutic angiogenesis in Buerger's disease: reviewing the treatment landscape.","authors":"Antoine J Ribieras, Yulexi Y Ortiz, Zhao-Jun Liu, Omaida C Velazquez","doi":"10.1177/26330040211070295","DOIUrl":null,"url":null,"abstract":"<p><p>Thromboangiitis obliterans, also known as Buerger's disease, is a rare inflammatory vasculitis that predominantly develops in smokers and characteristically affects the small- and medium-sized peripheral arteries and veins. Patients typically present with extremity claudication, but symptoms may progress to rest pain and tissue loss, especially in those unable to abstain from tobacco use. Unfortunately, traditional medical treatments are largely ineffective and due to the small caliber of affected vessels and lack of suitable distal targets or venous conduits, endovascular and open surgical approaches are often not possible. Eventually, a significant number of patients require major amputation. For these reasons, much research effort has been made in developing techniques of therapeutic angiogenesis to improve limb perfusion, both for atherosclerotic peripheral arterial disease and the smaller subset of patients with critical limb ischemia due to Buerger's disease. Neovascularization in response to ischemia relies on a complex interplay between the local tissue microenvironment and circulating stem and progenitor cells. To date, studies of therapeutic angiogenesis have therefore focused on exploiting known angiogenic factors and stem cells to induce neovascularization in ischemic tissues. This review summarizes the available clinical data regarding the safety and efficacy of various angiogenic therapies, notably injection of naked DNA plasmids, viral gene constructs, and cell-based preparations, and describes techniques for potentiating <i>in vivo</i> efficacy of gene- and cell-based therapies as well as ongoing developments in exosome-based cell-free approaches for therapeutic angiogenesis.</p><p><strong>Plain language title and summary: </strong><i>A review of available and emerging treatments for improving blood flow and wound healing in patients with Buerger's disease, a rare disorder of blood vessels</i> Buerger's disease is a rare disorder of the small- and medium-sized blood vessels in the arms and legs that almost exclusively develops in young smokers. Buerger's disease causes inflammation in arteries and veins, which leads to blockage of these vessels and reduces blood flow to and from the extremities. Decreased blood flow to the arms and legs can lead to development of nonhealing wounds and infection for which some patients may eventually require amputation. Unfortunately, traditional medical and surgical treatments are not effective in Buerger's disease, so other methods for improving blood flow are needed for these patients. There are several different ways to stimulate new blood vessel formation, both in humans and animal models. The most common treatments involve injection of DNA or viruses that express genes related to blood vessel formation or, alternatively, stem cell-based treatments that help regenerate blood vessels and repair wound tissue. This review explores how safe and effective these various treatments are and describes recent research developments that may lead to better therapies for patients with Buerger's disease and other vascular disorders.</p>","PeriodicalId":75218,"journal":{"name":"Therapeutic advances in rare disease","volume":"3 ","pages":"26330040211070295"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/81/10.1177_26330040211070295.PMC10032470.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic advances in rare disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/26330040211070295","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Thromboangiitis obliterans, also known as Buerger's disease, is a rare inflammatory vasculitis that predominantly develops in smokers and characteristically affects the small- and medium-sized peripheral arteries and veins. Patients typically present with extremity claudication, but symptoms may progress to rest pain and tissue loss, especially in those unable to abstain from tobacco use. Unfortunately, traditional medical treatments are largely ineffective and due to the small caliber of affected vessels and lack of suitable distal targets or venous conduits, endovascular and open surgical approaches are often not possible. Eventually, a significant number of patients require major amputation. For these reasons, much research effort has been made in developing techniques of therapeutic angiogenesis to improve limb perfusion, both for atherosclerotic peripheral arterial disease and the smaller subset of patients with critical limb ischemia due to Buerger's disease. Neovascularization in response to ischemia relies on a complex interplay between the local tissue microenvironment and circulating stem and progenitor cells. To date, studies of therapeutic angiogenesis have therefore focused on exploiting known angiogenic factors and stem cells to induce neovascularization in ischemic tissues. This review summarizes the available clinical data regarding the safety and efficacy of various angiogenic therapies, notably injection of naked DNA plasmids, viral gene constructs, and cell-based preparations, and describes techniques for potentiating in vivo efficacy of gene- and cell-based therapies as well as ongoing developments in exosome-based cell-free approaches for therapeutic angiogenesis.

Plain language title and summary: A review of available and emerging treatments for improving blood flow and wound healing in patients with Buerger's disease, a rare disorder of blood vessels Buerger's disease is a rare disorder of the small- and medium-sized blood vessels in the arms and legs that almost exclusively develops in young smokers. Buerger's disease causes inflammation in arteries and veins, which leads to blockage of these vessels and reduces blood flow to and from the extremities. Decreased blood flow to the arms and legs can lead to development of nonhealing wounds and infection for which some patients may eventually require amputation. Unfortunately, traditional medical and surgical treatments are not effective in Buerger's disease, so other methods for improving blood flow are needed for these patients. There are several different ways to stimulate new blood vessel formation, both in humans and animal models. The most common treatments involve injection of DNA or viruses that express genes related to blood vessel formation or, alternatively, stem cell-based treatments that help regenerate blood vessels and repair wound tissue. This review explores how safe and effective these various treatments are and describes recent research developments that may lead to better therapies for patients with Buerger's disease and other vascular disorders.

Abstract Image

Abstract Image

Abstract Image

Buerger病的治疗性血管生成:综述治疗前景。
血栓闭塞性脉管炎,也称为伯格病,是一种罕见的炎症性血管炎,主要发生在吸烟者身上,其特征是影响中小型外周动脉和静脉。患者通常表现为四肢跛行,但症状可能会发展为休息疼痛和组织损失,尤其是那些无法戒烟的患者。不幸的是,传统的医疗方法在很大程度上是无效的,并且由于受影响血管的口径较小,并且缺乏合适的远端靶点或静脉导管,血管内和开放式手术方法通常是不可能的。最终,大量患者需要进行大截肢手术。出于这些原因,人们在开发治疗性血管生成技术以改善肢体灌注方面进行了大量研究,无论是针对动脉粥样硬化性外周动脉疾病还是因伯格氏病导致的少数严重肢体缺血患者。缺血反应的新生血管依赖于局部组织微环境与循环干细胞和祖细胞之间的复杂相互作用。因此,迄今为止,治疗性血管生成的研究主要集中在利用已知的血管生成因子和干细胞来诱导缺血组织中的血管生成。这篇综述总结了关于各种血管生成疗法的安全性和有效性的可用临床数据,特别是注射裸DNA质粒、病毒基因构建体和基于细胞的制剂,并描述了增强基于基因和细胞的治疗的体内疗效的技术,以及用于治疗血管生成的基于外泌体的无细胞方法的持续发展。简明标题和摘要:对改善Buerger病患者血流和伤口愈合的现有和新兴治疗方法的综述Buerger氏病是一种罕见的血管疾病,几乎只发生在年轻吸烟者身上。伯格氏病会导致动脉和静脉发炎,从而导致这些血管堵塞,并减少往返四肢的血液流动。流向手臂和腿部的血流量减少会导致无法愈合的伤口和感染,一些患者最终可能需要截肢。不幸的是,传统的医学和外科治疗对伯格氏病无效,因此这些患者需要其他改善血流的方法。在人类和动物模型中,有几种不同的方法可以刺激新血管的形成。最常见的治疗方法包括注射表达与血管形成相关基因的DNA或病毒,或者基于干细胞的治疗方法,帮助血管再生和修复伤口组织。这篇综述探讨了这些不同的治疗方法的安全性和有效性,并描述了最近的研究进展,这些研究进展可能会为伯格病和其他血管疾病患者带来更好的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信